hrcak mascot   Srce   HID

Libri Oncologici : Croatian Journal of Oncology, Vol. 43 No. 1-3, 2015.

Pregledni rad

Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs

Vesna Pavlica ; Hospital Pharmacy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Robert Šeparović ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ana Tečić Vuger ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Tajana Silovski ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Andreja Jurić ; Department of Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (171 KB) str. 59-65 preuzimanja: 71* citiraj
APA 6th Edition
Pavlica, V., Šeparović, R., Tečić Vuger, A., Silovski, T. i Jurić, A. (2015). Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs. Libri Oncologici, 43 (1-3), 59-65. Preuzeto s https://hrcak.srce.hr/189822
MLA 8th Edition
Pavlica, Vesna, et al. "Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs." Libri Oncologici, vol. 43, br. 1-3, 2015, str. 59-65. https://hrcak.srce.hr/189822. Citirano 21.03.2019.
Chicago 17th Edition
Pavlica, Vesna, Robert Šeparović, Ana Tečić Vuger, Tajana Silovski i Andreja Jurić. "Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs." Libri Oncologici 43, br. 1-3 (2015): 59-65. https://hrcak.srce.hr/189822
Harvard
Pavlica, V., et al. (2015). 'Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs', Libri Oncologici, 43(1-3), str. 59-65. Preuzeto s: https://hrcak.srce.hr/189822 (Datum pristupa: 21.03.2019.)
Vancouver
Pavlica V, Šeparović R, Tečić Vuger A, Silovski T, Jurić A. Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs. Libri Oncologici [Internet]. 2015 [pristupljeno 21.03.2019.];43(1-3):59-65. Dostupno na: https://hrcak.srce.hr/189822
IEEE
V. Pavlica, R. Šeparović, A. Tečić Vuger, T. Silovski i A. Jurić, "Systemic therapy of ovarian cancer – the mechanism of action of antineoplastic drugs", Libri Oncologici, vol.43, br. 1-3, str. 59-65, 2015. [Online]. Dostupno na: https://hrcak.srce.hr/189822. [Citirano: 21.03.2019.]

Sažetak
Ovarian cancer treatment consists of surgical options and systemic antineoplastic therapy. Systemic medicamentous therapy, involves a choice of classic chemotherapy and targeted biological treatment. Cytotoxic drugs act nonspecifi cally on tumor cells, damaging also certain proportion of healthy cells in human body. Such drugs act on the basis of impact on the life cycle of cells. Some work throughout the whole cell cycle, phase nonspecifi cally, while others work somewhat more specifi cally for certain phase of cell cycle. Among cell cycle nonspecifi c antineoplastic drugs, a platinum compounds, cisplatin
and carboplatin play the main role. A cell cycle phase specifi c activity is seen in a few groups of antineoplastic drugs, among which a signifi cant role in the therapy of ovarian cancer is played by taxanes paclitaxel and docetaxel, camptothecin analogue topotecan, podophyllotoxin etoposide, pyrimidine antagonist gemcitabine and anthracycline doxorubicin. In the treatment of ovarian cancer a signifi cant place is also held by two biological medicines, the so-called “on targeted drugs”,
VEGF inhibitor bevacizumab and PARP inhibitor olaparib.

Ključne riječi
systemic antineoplastic therapy; ovarian cancer; chemotherapeutics; biological drugs; cell cycle; cisplatin; carboplatin; taxanes; paclitaxel; docetaxel; topotecan; etoposide; gemcitabine; doxorubicin; bevacizumab; olaparib

Hrčak ID: 189822

URI
https://hrcak.srce.hr/189822

[hrvatski]

Posjeta: 107 *